Tsuchiya Y, Byrne D, Burgess S, Bormann J, Bakovic J, Huang Y, et al. Covalent Aurora A regulation by the metabolic integrator coenzyme A. Redox Biol. 2020;28:101318 pubmed publisher

Niemietz C, Fleischhauer L, Sandfort V, Guttmann S, Zibert A, Schmidt H. Hepatocyte-like cells reveal novel role of SERPINA1 in transthyretin amyloidosis. J Cell Sci. 2018;131: pubmed publisher

Miller M, Pal A, Albusairi W, Joo H, Pappas B, Haque Tuhin M, et al. Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis. J Med Chem. 2018;61:7862-7876 pubmed publisher

Lourenço P, Silva S, Friões F, Alvelos M, Amorim M, Couto M, et al. Low prealbumin is strongly associated with adverse outcome in heart failure. Heart. 2014;100:1780-5 pubmed publisher

Lozeron P, Lacroix C, Théaudin M, Richer A, Gugenheim M, Adams D, et al. An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation. Amyloid. 2013;20:188-92 pubmed publisher

Petrakis I, Mavroeidi V, Stylianou K, Andronikidi E, Lioudaki E, Perakis K, et al. Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis. Amyloid. 2013;20:164-72 pubmed publisher

Beirão J, Matos M, Beirão I, Costa P, Torres P. Topical cyclosporine for severe dry eye disease in liver-transplanted Portuguese patients with familial amyloidotic polyneuropathy (ATTRV30M). Eur J Ophthalmol. 2013;23:156-63 pubmed publisher

Adams D, Samuel D, Slama M. [Treatment of familial amyloid polyneuropathy]. Presse Med. 2012;41:793-806 pubmed publisher

Kodaira M, Morita H, Shimojima Y, Ikeda S. Electrophysiological features of familial amyloid polyneuropathy in endemic area. Amyloid. 2011;18:10-8 pubmed publisher

Trivella D, Bleicher L, Palmieri L, Wiggers H, Montanari C, Kelly J, et al. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. J Struct Biol. 2010;170:522-31 pubmed publisher

Dardiotis E, Koutsou P, Zamba Papanicolaou E, Vonta I, Hadjivassiliou M, Hadjigeorgiou G, et al. Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci. 2009;284:158-62 pubmed publisher

Said G, Plante Bordeneuve V. Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci. 2009;284:149-54 pubmed publisher

Munar Ques M, Martinez Nadal J, Torres Rovira J, Sole M, Zabay Becerril J, Mulet Ferrer J. Finding of vascular amyloid TTR in inferior nasal concha in a patient with FAP TTRVal30Met. Amyloid. 2008;15:272-4 pubmed publisher

Koike H, Kawagashira Y, Iijima M, Yamamoto M, Hattori N, Tanaka F, et al. Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol. 2008;255:1526-33 pubmed publisher

Rudolph T, Kurz M, Farbu E. Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history. Clin Med Res. 2008;6:80-2 pubmed publisher

Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, et al. Reduced transthyretin expression in sera of lung cancer. Cancer Sci. 2007;98:1617-24 pubmed

Ito T, Sakakibara R, Ito S, Uchiyama T, Liu Z, Yamamoto T, et al. Mechanism of constipation in familial amyloid polyneuropathy: a case report. Intern Med. 2006;45:1173-5 pubmed

Sobue G. [Clinical phenotype of Charcot-Marie-Tooth disease (CMT) and familial amyloid polyneuropathy (FAP)]. Rinsho Shinkeigaku. 2003;43:769-74 pubmed

Ohmori H, Ando Y, Makita Y, Onouchi Y, Nakajima T, Saraiva M, et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J Med Genet. 2004;41:e51 pubmed

Koga T, Ando E, Hirata A, Fukushima M, Kimura A, Ando Y, et al. Vitreous opacities and outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy. Am J Ophthalmol. 2003;135:188-93 pubmed

Harada T, Ishizaki F, Togo M, Yamashita H, Nitta K, Date Y, et al. [A sporadic case of late-onset familial amyloid polyneuropathy type I (transthyretin Met 30-associated familial amyloid polyneuropathy) inborn habitant of Ehime prefecture]. No To Shinkei. 2002;54:615-9 pubmed

Figueras J, Munar Ques M, Pares D, Torras J, Fabregat J, Rafecas A, et al. [Sequential liver transplantation: description of the first three patients in Spain]. Med Clin (Barc). 2001;116:377-9 pubmed

Herlenius G, Larsson M, Ericzon B. FAP World Transplant Register and domino/sequential register update. Transplant Proc. 2001;33:1367 pubmed

Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr O, Obayashi K, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci. 1999;171:19-23 pubmed

Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122 ( Pt 10):1951-62 pubmed

Monteiro E, Perdigoto R, Furtado A. Liver transplantation for familial amyloid polyneuropathy. Hepatogastroenterology. 1998;45:1375-80 pubmed

Inouye H, Domingues F, Damas A, Saraiva M, Lundgren E, Sandgren O, et al. Analysis of x-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: axially arrayed TTR monomers constitute the protofilament. Amyloid. 1998;5:163-74 pubmed

Suess K, Moch H, Epper R, Koller A, Dürmüller U, Mihatsch M. [Heterogeneity of seminal vesicle amyloid. Immunohistochemical detection of lactoferrin and amyloid of the prealbumin-transthyretin type]. Pathologe. 1998;19:115-9 pubmed

Saraiva M, Almeida M, Alves I, Bonifacio M, Damas A, Palha J, et al. Modulating conformational factors in transthyretin amyloid. Ciba Found Symp. 1996;199:47-52; discussion 52-7 pubmed

Shimizu H, Ishikawa K, Kobayashi H, Murakami T, Nakazato M, Miura K, et al. [Familial amyloidotic polyneuropathy with a transthyretin variant (Val30-->Leu)]. No To Shinkei. 1996;48:175-8 pubmed

Hanes D, Zech L, Murrell J, Benson M. Metabolism of normal and Met30 transthyretin. Adv Food Nutr Res. 1996;40:149-55 pubmed

Ciulla T, Tolentino F, Morrow J, Dryja T. Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Surv Ophthalmol. 1995;40:197-206 pubmed

Nelson K, Pollack S, Hellstrom K. Specific anti-tumor responses by cultured immune spleen cells. I. In vitro culture method and initial characterization of factors which block immune cell-mediated cytotoxicity in vitro. Int J Cancer. 1975;15:806-14 pubmed